The Size of the Mycoplasma Testing Market in the Asia Pacific is valued at USD 137.85 Million in 2022 and is expected to be growing at a CAGR of 16.7%, to reach USD 298.37 Million by 2027 during the forecast period 2022 to 2027.
Mycoplasma spreads easily through droplets through cell culture and can persist in a dry form for months. Mycoplasma infection is complex to see under a microscope and requires specific tests to be detected. Infection can have an acute impact on experimental work depending on the species present. These will lead to cross contamination of cell cultures and drive the growth rate for mycoplasma testing.
Major bio pharmaceutical companies operating in the market are making various strategic investments, such as launching innovative products, advancing research and development, and technological innovations, which are gaining popularity in the mycoplasma testing market and expand the consumer base to survive in a competitive business environment in APAC regions.
Lack of trained / skilled molecular biologists is expected to slow the market growth during the forecast period. Mycoplasma testing requires certain specialized skills seen in professional from life sciences, pharmaceuticals, electronics and software industries. The lack of trained personnel capable of conducting molecular biology experiments and interpreting the results is a major limitation of testing and containment of COVID-19 in developing countries.
The growing incidences of mycoplasma pneumonia cross infection in many COVID-19 patients is expected to drive the market for mycoplasma testing during the forecast period. The presence of M. pneumonia cross infection increases the necessity to get the patients tested for COVID-19, increasing the demand for routine diagnostic tests for respiratory pathogens such as M. pneumonia. Co-infections in COVID-19 cases have a significant likelihood of being caused by Mycoplasma pneumoniae.
The high degree of consolidation is a significant barrier to entry for new entrants, which in turn is expected to restrict investment and therefore slow the growth potential of this market.
This research report on the Asia Pacific Mycoplasma Testing Market has been segmented and sub-segmented into the following categories
China accounted for the majority of the APAC mycoplasma testing market, and China will continue to be one of the fastest growing countries in this group of regional markets. Led by countries such as Australia, India and South Korea, the Asia-Pacific market is expected to reach US $ 196.9 million in the upcoming year.
China, the world's second-largest economy, is expected to reach a projected market size of US $ 296.3 million by 2027, with a CAGR of 15% over the analysis period from 2022 to 2027. Others Notable geographic market includes Japan reaching forecast growth of 7.6% and 9.8% over the period 2022 - 2027.
Much of this regional market growth can be attributed mainly to the development of the biotechnology and pharmaceutical industries, the high rate of adoption of new technologies and the large number of life science research studies conducted in this region along with regulatory policies adopted by health organizations to improve the quality of biosafety in countries such as China and India.
M. pneumoniae co-infection ranged from 1.2% to 40.9% depending on the population and diagnostic tests used, and the combined prevalence of M. pneumoniae co-infection among COVID-19 patients has been reported to 17.6%.These data suggest the healthy growth of mycoplasma testing in the APAC in the forecasted period 2022-2027.
Top Companies dominating the Asia Pacific Mycoplasma Testing Market Profiled in the Report are PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, WuXi AppTec.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org